Robert H. Eckel, MD, Silvio Litovsky, MD, and Anand Srivastava, MD, MPH, explored differences between type 1 and type 2 diabetes in respect to cardiovascular and kidney complications, then interpreted what this means for future research and ongoing clinical care.
Ihr Browser kann dieses Video nicht wiedergeben. Video transcript If I think about my research, I have been working on many vascular growth factors about…
The mechanisms driving the cardiovascular and renal benefits of therapies targeting intestinal hormones in type 2 diabetes are still not fully understood. We propose that…
Join us for the 5K@EASD Virtual Challenge from 12-17 September, 2025! This year, we are celebrating Novo Nordisk’s 20th anniversary of sponsorship of the 5K@EASD.…
The European Congress of Endocrinology (ECE) will take place in Prague, Czech Republic, from 9 – 12 May 2026.Â
The future of diabetes care is evolving—Are you ready for what’s next? What’s Next? is an exclusive limited-series podcast that takes you inside the latest…
Academic detailing plus pre-visit patient activation was associated with sustained diabetes deprescribing rates at 12 months in older adults with T2D.
The Endocrine Society is pleased to welcome Carol Lange, PhD, who takes office during ENDO 2025 in San Francisco. Lange succeeds John Newell-Price, MD, PhD,…
Linzagolix therapy was associated with significantly reduced heavy menstrual bleeding by week 52 among patients with uterine fibroids.
Isolated hypothyroxinemia, but not subclinical hypothyroidism, is tied to a high likelihood for gestational diabetes, researchers reported in The Lancet Diabetes & Endocrinology. Subclinical hypothyroidism…
News from our experts in diabetes, thyroid, menopause, reproduction, endocrine-disrupting chemicals, osteoporosis, obesity, and other hormone health topics.
